Banco Bilbao Vizcaya Argentaria S.A. Increases Stake in Biogen Inc. $BIIB

Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 20.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 138,654 shares of the biotechnology company’s stock after buying an additional 23,782 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A. owned 0.09% of Biogen worth $19,404,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC purchased a new stake in shares of Biogen during the second quarter worth $25,000. Rothschild Investment LLC boosted its holdings in Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares during the period. Accredited Wealth Management LLC boosted its holdings in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares during the period. WFA of San Diego LLC acquired a new position in Biogen during the 2nd quarter worth $32,000. Finally, True Wealth Design LLC grew its stake in Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 1.8%

NASDAQ:BIIB opened at $181.55 on Monday. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $202.41. The stock has a market cap of $26.64 billion, a P/E ratio of 20.61, a P/E/G ratio of 1.44 and a beta of 0.15. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The stock has a 50-day simple moving average of $184.10 and a 200-day simple moving average of $167.19.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Guggenheim boosted their price objective on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Jefferies Financial Group upped their target price on shares of Biogen from $190.00 to $210.00 and gave the stock a “buy” rating in a research note on Friday, November 28th. HC Wainwright raised their target price on shares of Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, BMO Capital Markets lifted their price target on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research note on Friday, February 6th. Twelve research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $205.04.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.18% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.